Literature DB >> 15812530

Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning.

P Veys1, K Rao, P Amrolia.   

Abstract

The optimal preparation for stem cell transplantation (SCT) in children with congenital immunodeficiencies is currently unknown. In all, 81 children with immunodeficiency underwent 82 SCTs using reduced-intensity conditioning (RIC). The incidence of significant GVHD was low; viral reactivation was prominent with an unexpected increase in EBV reactivation; immune reconstitution was similar between different donor groups and comparable to conventional SCT. Overall, 68/81 (84%) survive with no significant difference between donor types or between severe combined immunodeficiency (SCID) and non-SCID diseases. Findings suggest a significant survival advantage in the unrelated donor setting for RIC compared to conventional SCT.

Entities:  

Mesh：

Year:  2005        PMID： 15812530     DOI： 10.1038/sj.bmt.1704846

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  8 in total

Review 1.  Haemopoietic stem cell transplantation for genetic disorders.

Authors:  C G Steward; A Jarisch
Journal:  Arch Dis Child       Date:  2005-12       Impact factor: 3.791

2.  Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.

Authors:  Jennifer Cuellar-Rodriguez; Alexandra F Freeman; Jennifer Grossman; Helen Su; Mark Parta; Heardley Murdock; Nirali Shah; Catherine Bollard; Heidi H Kong; Niki Moutsopoulos; Kelly Stone; Juan Gea-Banacloche; Steven M Holland; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-27       Impact factor: 5.742

3.  Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.

Authors:  A Lawitschka; M Faraci; I Yaniv; P Veys; P Bader; J Wachowiak; G Socie; M D Aljurf; M Arat; J J Boelens; R Duarte; A Tichelli; C Peters
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

4.  Radiosensitive severe combined immunodeficiency disease.

Authors:  Christopher C Dvorak; Morton J Cowan
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

5.  Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome.

Authors:  N C Patel; J L Gallagher; T R Torgerson; A L Gilman
Journal:  J Clin Immunol       Date:  2015-05-12       Impact factor: 8.317

6.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

7.  Hematopoietic stem cell transplantation for pediatric patients with primary immunodeficiency diseases at All Children's Hospital/University of South Florida.

Authors:  A Petrovic; M Dorsey; J Miotke; C Shepherd; N Day
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

8.  Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

Authors:  Akira Nishimura; Yuki Aoki; Yasuyoshi Ishiwata; Takuya Ichimura; Junichi Ueyama; Yuta Kawahara; Takahiro Tomoda; Maiko Inoue; Kazuaki Matsumoto; Kento Inoue; Haruka Hiroki; Shintaro Ono; Motoi Yamashita; Tsubasa Okano; Mari Tanaka-Kubota; Miho Ashiarai; Satoshi Miyamoto; Reiji Miyawaki; Chika Yamagishi; Mari Tezuka; Teppei Okawa; Akihiro Hoshino; Akifumi Endo; Masato Yasuhara; Takahiro Kamiya; Noriko Mitsuiki; Toshiaki Ono; Takeshi Isoda; Masakatsu Yanagimachi; Daisuke Tomizawa; Masayuki Nagasawa; Shuki Mizutani; Michiko Kajiwara; Masatoshi Takagi; Hirokazu Kanegane; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-02-01       Impact factor: 8.317
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.